ClinicalTrials.gg
RecruitingNCT05652361CoBot2Updated Aug 27, 2026

Machine Learning-based Surgical Guidance System for Robot-assisted Rectal Surgery

An interventional study of Additional visualisation of surgical assistance during surgery in Rectum Cancer, sponsored by Technische Universität Dresden. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Technische Universität Dresden · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Rectal Neoplasms with a site in Germany — 17 open to participants now, 27 under way, 4 of them phase 3. Rectal Neoplasms · Germany.

Planned enrollment
59th of 62
12 · median 124
Started
2026
with 2 others
No phase
11 of 78
5 open now
Primary completion
2027-01
later than 14 of 26 live
Registered
64th of 78
by date

Among the 78 studies in Rectal Neoplasms with a site in Germany, this one is the 59th largest by planned enrollment of the 62 interventional ones that give a count, is one of 3 that started in 2026, is one of 11 with no phase, reaches primary completion later than 14 of the 26 other live ones, and was the 64th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

17 of the 78 studies in Rectal Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Rectal Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

The aim of the study is to evaluate the technical feasibility and applicability of a surgical assistance system based on image recognition algorithms in a first-in-human pilot study. In addition, this study will provide preliminary data on the oncological outcome of the assistance system.

03

Conditions studied

  • Rectum Cancer

Browse trials for

Keywords

  • Robotic Surgery
  • Total mesorectal excision
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with rectal cancer scheduled for robot-assisted rectal resection
  • Intact preoperative urogenital/rectal function
  • Full capability of consent

Exclusion criteria

Exclusion Criteria:

  • Previous/Second malignant disease \<5 years before diagnosis of rectal cancer
  • Previous abdominal surgery, except for laparoscopic appendectomy, laparoscopic cholecystectomy or Cesarean section
  • Pregnant or breastfeeding women
  • Addiction or illness that prevent the person concerned from assessing the nature and scope of the clinical trial and its possible consequences
  • indication that the participant is unlikely to comply with the trial protocoll (e.g. lack of compliance)
  • official or court order for involuntary hospitalization
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Additional visualisation of surgical assistance during surgery

    Other: Additional visualisation of surgical assistance during surgery

Interventions

  • OtherAdditional visualisation of surgical assistance during surgery

    Robot-assisted anterior rectal resection using daVinci® system as CE-marked gold standard with additional visualization of surgical assistance functions based on machine learning techniques

06

What researchers measure

Primary outcomes

  1. Incidence of discrepancies between the surgeon's preparation and the prediction of the CoBot system

    System discrepancy score quantifying major misspecifications of the CoBot system in comparison to the surgeon's action

    Time frame: 72 hours after Surgery

Secondary outcomes

  1. Operating time [min]

    Time from skin incision until placement of last skin staple/suture

    Time frame: During Surgery

  2. Duration of postoperative hospital stay [days]

    Postoperative day 1 until day of discharge

    Time frame: At day of discharge, assessed up to 5 days

  3. Duration of postoperative intermediate/intensive care unit stay [days]

    Postoperative day 1 until day of discharge

    Time frame: At day of discharge, assessed up to 5 days

  4. Frequency of peri-operative morbidity after resection

    Frequency of peri-operative complications after surgery until Day of Discharge

    Time frame: At day of discharge, assessed of up to 5 days

  5. Kind of peri-operative morbidity after resection

    Kind of peri-operative complications after surgery until day of discharge

    Time frame: At day of discharge, assessed of up to 5 days

  6. Assessment of the circumferential resection margin (CRM)

    Rate of R0 resections

    Time frame: At day of discharge, assessed up to 5 days

  7. Number of resected lymphnodes

    Number of lymphnodes resected during surgery

    Time frame: During surgery

  8. Assessment of pelvic function before and after rectal resection

    Rectal function will be assessed preoperatively and 12-15 months postoperatively using the standard LARS score questionnaire, resulting in a score between 0 and 42. Higher scores mean a worse outcome (worse pelvic function).

    Time frame: 15 months

  9. Rectal sphincter function before and after rectal resection

    Sphincter function will be assessed by manometry preoperatively and 12 - 15 months postoperatively

    Time frame: 15 months

  10. Assessment of the difficulty of the preparation

    Surgeon questionnaire, the questionnaire qualitatively assesses nine items, each item scoring from "not at all" to "very much", evaluated individually

    Time frame: 48 hours after surgery

  11. Assessment of usability of guidance system

    One-time final survey of all participating surgeons, the questionnaire qualitatively assesses nine items, each item scoring from "not at all" to "very much", evaluated individually

    Time frame: Through study completion, an average of 6 months

07

Study locations

1 of 1 sites recruiting
  • Department of Visceral, Thoracic and Vascular Surgery University Hospital Carl Gustav Carus Technische Universität Dresden
    Dresden, Saxony 01307, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jan 2027, 11 months after the start.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 11 months is below that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2022
First posted
Dec 15, 2022
StartActual
Feb 25, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Dec 2027
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05652361
Collaborators
German Cancer Research Center
Responsible party
Sponsor
First posted
Dec 15, 2022
Start date
Feb 25, 2026
Primary completion
Jan 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 27, 2026

Study contacts

Marius Distler, Prof. Dr.
Contact
marius.distler@ukdd.de
+49 351 458 4098
Fiona Kolbinger, Dr.
Contact
fiona.kolbinger@ukdd.de
+49 351 458 4098
Marius Distler, Prof. Dr.
principal investigator · University Hospital Carl Gustav Carus Dresden

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion